Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma

被引：47

作者：

Orchard, K

Barrington, S

Buscombe, J

Hilson, A

Prentice, HG

Mehta, A

机构：

[1] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, London, England

[2] Kings & St Thomass Hosp, Clin PET Ctr, London, England

[3] UCL Royal Free & Univ Coll Med Sch, Dept Nucl Med, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 117卷 / 01期

关键词：

myeloma; FDG-PET; imaging; occult disease; non-secretory;

D O I：

10.1046/j.1365-2141.2002.03407.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Positron emission tomography with 2-deoxy-2-[18]fluoro-d-glucose (FDG-PET) imaging has been extensively used to detect occult metastatic malignant lesions in patients with carcinoma. We describe its use in three patients with multiple myeloma, each representing a particular clinical situation in which this imaging modality offered advantages over plain radiography, computerized tomography or magnetic resonance imaging. FDG-PET provides a whole body image showing sites of occult disease. This is of particular value in patients with non-secretory myeloma, solitary plasmacytoma or for those that relapse with focal disease following autologous or allogeneic stem cell transplantation.

引用

页码：133 / 135

页数：3

共 5 条

[1]

Durie BGM, 1999, J NUCL MED, V40, p61P

[2]

ElShirbiny AM, 1997, J NUCL MED, V38, P1208

[3] Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].